|
Brentuximab vedotin (SGN-35) is currently
in a phase II single-agent clinical trial for patients with relapsed
or refractory systemic ALCL.
For more information about brentuximab vedotin, click on the
link to the left. You may also click on the link below to go
directly to the clinicaltrials.gov web site for more details about
this clinical trial.
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large
Cell Lymphoma
For general information about clinical trials, click on
the About Clinical Trials page to the left. |